Corneal Endothelial Cell Dynamics and Dystrophies

The corneal endothelium is a specialised monolayer of hexagonal cells on the inner surface of the cornea that regulates stromal hydration through active ionic transport and barrier functions. Unlike other ocular epithelia, human corneal endothelial cells (HCECs) possess extremely limited proliferative capacity in vivo, rendering the layer highly susceptible to age-related cell loss, injury and genetic perturbations. Progressive decline in endothelial cell density below a critical threshold leads to stromal oedema, loss of transparency and visual impairment. Posterior corneal dystrophies, most notably Fuchs endothelial corneal dystrophy (FECD), arise from inherited and environmental factors that disrupt endothelial integrity, promote extracellular matrix aberrations in Descemet membrane and induce cell apoptosis. Recent advances in molecular genetics have revealed trinucleotide repeat expansions, single-nucleotide variants and sex-specific risk loci that underpin FECD pathogenesis. Complementary studies in tissue engineering and pharmacological modulation seek to overcome the proliferative blockade of HCECs, employing small-molecule inhibitors, gene-editing approaches and cell-based graft alternatives to restore or replace dysfunctional endothelia. Collectively, this field seeks to integrate fundamental insights into cell dynamics with translational strategies to preserve corneal clarity and reduce reliance on donor tissues.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Corneal Endothelial Cell Dynamics and Dystrophies publication trend

The graph below shows the total number of articles in corneal endothelial cell dynamics and dystrophies across all publications each year (not limited to Nature Index journals).

Technical terms

Corneal endothelium: A monolayer of hexagonal cells on the posterior cornea responsible for deturgescence via ionic pumps and barrier functions.

Endothelial pump function: Active transport of ions (primarily Na+ and K+) to maintain stromal dehydration and corneal transparency.

Corneal dystrophy: A group of genetically determined, bilateral non-inflammatory disorders affecting corneal structure and clarity.

Fuchs endothelial corneal dystrophy (FECD): A posterior corneal dystrophy characterised by accelerated endothelial loss, guttae formation in Descemet membrane and progressive corneal oedema.

Rho kinase inhibitor (ROCK inhibitor): A small-molecule compound that modulates actomyosin contractility to enhance cell adhesion, proliferation and wound healing in endothelial cultures.

References

1. Corneal endothelial dysfunction treatments: Recent advances in non-invasive treatment strategies. Nano Today (2025).
2. A Common Trinucleotide Repeat Expansion within the Transcription Factor 4 (TCF4, E2-2) Gene Predicts Fuchs Corneal Dystrophy. PLOS ONE (2012).
3. Corneal dystrophies. Orphanet Journal of Rare Diseases (2009).
4. Inhibition of TGF-β Signaling Enables Human Corneal Endothelial Cell Expansion In Vitro for Use in Regenerative Medicine. PLOS ONE (2013).
5. Genome-wide association study identifies three novel loci in Fuchs endothelial corneal dystrophy. Nature Communications (2017).
6. Ultraviolet A light induces DNA damage and estrogen-DNA adducts in Fuchs endothelial corneal dystrophy causing females to be more affected. Proceedings of the National Academy of Sciences of the United States of America (2019).